The BETAMI–DANBLOCK trial, encompassing 5,574 patients with myocardial infarction (MI) and preserved left ventricular function, demonstrated that beta-blocker therapy significantly reduces the risk of death and major adverse cardiovascular events (MACE). With a relative risk reduction of 15% and nearly 2% absolute reduction in risk, the study established the efficacy of beta-blockers in contemporary MI management, complementing existing secondary prevention strategies. Published in the NEJM, this trial is pivotal for modern treatment protocols.

Source: NEJM